May 2007
Volume 48, Issue 13
ARVO Annual Meeting Abstract  |   May 2007
Intravitreal Avastin vs Pegaptanib in Treatment of Choroidal Neovascular Membranes
Author Affiliations & Notes
  • R. Ratnakaram
    Ophthalmology, University of Florida, Gainesville, Florida
  • M. Peden
    Ophthalmology, University of Florida, Gainesville, Florida
  • S. Adams
    Ophthalmology, University of Florida, Gainesville, Florida
  • Footnotes
    Commercial Relationships R. Ratnakaram, None; M. Peden, None; S. Adams, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 3373. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R. Ratnakaram, M. Peden, S. Adams; Intravitreal Avastin vs Pegaptanib in Treatment of Choroidal Neovascular Membranes. Invest. Ophthalmol. Vis. Sci. 2007;48(13):3373.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose:: The worldwide intravitreal use of VEGF inhibitors is rapidly increasing for the treatment of choroidal neovascular membranes seen in age related macular degeneration as well as other neovascular processes. To date, Pegaptanib (Macugen) and Bevacizumab(Avastin) intra-vitreal injections have been the most frequently used VEGF inhibitors, with Lucentis being recently added. Data comparing outcomes with these medications is limited. The purpose of this study is to compare outcomes in patients receiving Pegaptanib or Bevacizumab.

Methods:: The Ophthalmology Service at the University of Florida has been using intravitreal VEGF inhibitors since May 2005. To date, 379 IV VEGF injections have been given (208 Avastin, 171 Macugen). This study will present a review of all injections given.

Results:: Patients receiving either Bevacizumab or Pegaptanib had an initial Visual Acuity ranging from 20/60 to count fingers. At six weeks follow-up, 13% percent of the patients receiving Pegaptanib showed some improvement in vision (range 1-2 lines), while 60% of patients receiving Bevacizumab showed improvement (range 1 to 3 lines). No complications or side effects were noted with either of the medication injection.

Conclusions:: In our retrospective chart review, at six weeks after treatment, we found Bevacizumab to be more effective than Pegaptanib in treating patients with exudative ARMD. We will be further reviewing our data for longterm benefit with either of these medications.

Keywords: age-related macular degeneration • neovascularization • retina 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.